Boston structural heart repair company's StarFlex device lands FDA pre-market approval for treatment of ventricular heart defects.
NMT Medical Inc.'s StarFlex ventricular septum repair implant landed pre-market approval from the federal Food & Drug Administration.
The Boston-based company's device is designed to be inserted into the hearts of patients with defects in the wall between the ventricular chambers.
The StarFlex implant closes the defect, preventing already-oxygenated blood from returning to the lungs before being pumped back into the body.
A Delaware jury sides with Johnson & Johnson's DePuy-Synthes subsidiary in a patent spat over 3...
Results of pivotal study on Covidien subsidiary eV3's Pipeline cerebral aneurysm device, published in...
Delphi Ventures' John Maroney joins ForSight Vision5 as president, CEO & Director as the...
Echo Therapeutics initiates discussions with the FDA on the regulatory pathway for its Symphony non-...
Study results revealed in Europe this week cast doubt on the efficacy of renal denervation for...